- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05882396
Rood's Approach and Oxaliplatin-induced Peripheral Neuropathy in Colorectal Cancer Patients
May 26, 2023 updated by: Shaimaa Mohamed Ahmed Elsayeh, Cairo University
Efficacy of Rood's Approach on Oxaliplatin-induced Peripheral Neuropathy in Colorectal Cancer Patients
Oxaliplatin-induced chronic peripheral neuropathy is of major concern to oncologists and patients as it has been shown to affect patients' health-related quality of life.
Although a number of interventions have been implicated, none of them can be recommended for clinical use.
This therapeutic failure reflects a poor understanding of the real mechanism of oxaliplatin-induced neuropathy.
However, oxidative stress is identified to be one of the main biomolecular dysfunctions in this neuropathy.
Rood's approach is a neurophysiological approach that is based on reflexes of the central nervous system in which the sensory stimulation provides desired muscular response and was specially designed for patients with motor control problems.
It was developed by Margeret Rood in 1940.
According to Rood, sensory stimulation can activate or deactivate the receptor by facilitation or inhibition, which makes it possible to get the desired muscular response.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
So, the purpose of the study is to investigate the efficiency of Rood's approach on oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shaimaa MA El Sayeh, PhD
- Phone Number: +201007766160
- Email: sh.sayeh87@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The patient can participate in the study if they had at least one cycle of oxaliplatin chemotherapy.
- Colorectal cancer patients who have oxaliplatin-induced peripheral neuropathy, the patients included in the study with mild to moderate neuropathy according to mTNS.
- Patients from both genders.
- Their ages range from 18 to 60 years old.
Exclusion Criteria:
- Patients who had a history of any other neuropathy as diabetic neuropathy.
- Patients with an unstable medical condition during chemotherapy.
- Patients who are starting new therapy or dose modification during the study period.
- Patients with morbid obesity "body mass index >40%".
- Patients with a history of non-surgically repaired nerve compression injuries such as carpal tunnel, brachial plexopathy, spinal stenosis, and spinal nerve root compression.
- Patients with a history of central nervous system primary or metastatic malignancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Rood's approach group
Thirty colorectal cancer patients have oxaliplatin-induced peripheral neuropathy.
|
Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.
Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
|
Active Comparator: Traditional physical therapy program group
Thirty colorectal cancer patients have oxaliplatin-induced peripheral neuropathy.
|
Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NCT-CTCAE peripheral neuropathy grading
Time Frame: Change from baseline at twelve weeks after the intervention
|
It consists of of 5 grades; Grade (1) is asymptomatic may be accompanied by loss of tendon reflex or paraesthesia.
Grade (2) is moderate symptoms which limit instrumental activities of daily life Grade (3) is severe symptoms which limit self-care activates of daily life.
Grade (4) is life threatening consequences or urgent intervention indicated.
Grade (5) is death.
|
Change from baseline at twelve weeks after the intervention
|
The Ntx-12 questionnaire
Time Frame: Change from baseline at twelve weeks after the intervention
|
It is comprised of 12 statements intended to measure the severity and impact of peripheral sensory neuropathy on patients' lives.
Patients were instructed to complete the Arabic version of the Ntx-12 and choose the number corresponding to how true each statement was for them using a Likert-type scale, with 0 indicating not at all; 1, a little bit; 2, somewhat; 3, quite a bit; and 4, very much.
|
Change from baseline at twelve weeks after the intervention
|
Brief Pain Inventory Short Form (BPI-SF) Bworst pain
Time Frame: Change from baseline at twelve weeks after the intervention
|
The BPI-SF assesses pain at its worst, least, average, and now (current pain).
Patients respond on 0-to-10 numerical rating scales.
Each scale presented as a row of equidistant numbers, where 0 = no pain^ and 10 = pain as bad as you can imagine.
|
Change from baseline at twelve weeks after the intervention
|
Total Neuropathy Score
Time Frame: Change from baseline at twelve weeks after the intervention
|
used to measure these constructs.
It includes 6 items graded from 0 to 4 according to the patients' symptoms, the total grade from 0 to 24.
The higher grade the worse neuropathy.
It graded as mild (1:9), moderate (10:19) and (20:24) severe.
|
Change from baseline at twelve weeks after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The 4-Stage Balance Test
Time Frame: Change from baseline at twelve weeks after the intervention
|
is a recommended measure from the Centers for Disease Control and Prevention STEADI (Stopping Elderly Accidents, Deaths, and Injuries) falls campaign to recognize fall risk.
An adult who cannot hold tandem stance for 10 seconds is at a higher risk for falls.
[18] Patient A was able to stand in tandem stance for 2 seconds on each side.
Patient B was able to stand on single leg stance for 10 seconds on each side
|
Change from baseline at twelve weeks after the intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Shaimaa MA El Sayeh, PhD, Lecturer at Faculty of Physical Therapy, Cairo University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2023
Primary Completion (Estimated)
December 28, 2023
Study Completion (Estimated)
January 11, 2024
Study Registration Dates
First Submitted
May 19, 2023
First Submitted That Met QC Criteria
May 26, 2023
First Posted (Actual)
May 31, 2023
Study Record Updates
Last Update Posted (Actual)
May 31, 2023
Last Update Submitted That Met QC Criteria
May 26, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Neuromuscular Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Peripheral Nervous System Diseases
Other Study ID Numbers
- P.T.REC/012/004322
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Rood's approach
-
Riphah International UniversityCompleted
-
Sahlgrenska University Hospital, SwedenVastra Gotaland RegionRecruitingMuscle Weakness | Muscle Atrophy | Hip Osteoarthritis | Arthroplasty Complications | Muscle InjurySweden
-
University of Sao Paulo General HospitalUniversity of Campinas, BrazilUnknown
-
Iuliu Hatieganu University of Medicine and PharmacyEmergency County Hospital Cluj-NapocaCompleted
-
Florida Orthopaedic InstituteOrthopaedic Trauma AssociationCompletedTibial FracturesUnited States
-
Sorlandet Hospital HFUnknown
-
Fraser Orthopaedic Research SocietyCompletedINfrapatellar Versus SUprapatellar Reamed Intramedullary Nailing for Fractures of the Tibia (INSURT)Tibial Fractures | Anterior Knee Pain SyndromeCanada, Spain
-
Cairo UniversityCompletedFacial Nerve Injuries | Subcondylar Process of Mandible Open FractureEgypt
-
Assiut UniversityUnknown
-
University Hospital, Clermont-FerrandUnknown